{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Vir Biotechnology, Inc."},"Symbol":{"label":"Symbol","value":"VIR"},"Address":{"label":"Address","value":"499 ILLINOIS STREET,SUITE 500, SAN FRANCISCO, California, 94158, United States"},"Phone":{"label":"Phone","value":"+1 415 906-4324"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, and acquisitions. The company's pipeline consists of product candidates targeting hepatitis B virus, or HBV, influenza A, human immunodeficiency virus, or HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue and license revenue."},"CompanyUrl":{"label":"Company Url","value":"https://www.vir.bio"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Aine M. Hanly","title":"Chief Technology Officer & Executive VP"},{"name":"Carey Hwang","title":"Senior Vice President-Clinical Research"},{"name":"Jennifer Towne","title":"Chief Scientific Officer & Executive VP"},{"name":"Marianne de Backer","title":"Chief Executive Officer & Director"},{"name":"Mark D. Eisner","title":"Chief Medical Officer & Executive Vice President"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}